share_log

MIRA Pharmaceuticals | 8-K: Current report

MIRA Pharmaceuticals | 8-K: Current report

MIRA Pharmaceuticals | 8-K:重大事件
美股SEC公告 ·  09/12 13:34

Moomoo AI 已提取核心信息

MIRA Pharmaceuticals held its 2024 Annual Meeting on September 12, 2024, with 63.72% of outstanding shares represented. Stockholders elected five directors: Erez Aminov, Michael Jerman, Matthew Del Giudice, M.D., Denil Nanji Shekhat, M.D., and Edward MacPherson, to serve until the next Annual Meeting.The appointment of Cherry Bekaert LLP as the independent registered public accounting firm for FY2024 was ratified. Shareholders also approved amendments to the 2022 Omnibus Incentive Plan to increase available shares. The proposal to adjourn the meeting if necessary was withdrawn as other proposals passed.Voting results showed strong support for all proposals, with director nominees receiving over 6.6 million votes each, and the accounting firm appointment garnering over 9.4 million votes in favor.
MIRA Pharmaceuticals held its 2024 Annual Meeting on September 12, 2024, with 63.72% of outstanding shares represented. Stockholders elected five directors: Erez Aminov, Michael Jerman, Matthew Del Giudice, M.D., Denil Nanji Shekhat, M.D., and Edward MacPherson, to serve until the next Annual Meeting.The appointment of Cherry Bekaert LLP as the independent registered public accounting firm for FY2024 was ratified. Shareholders also approved amendments to the 2022 Omnibus Incentive Plan to increase available shares. The proposal to adjourn the meeting if necessary was withdrawn as other proposals passed.Voting results showed strong support for all proposals, with director nominees receiving over 6.6 million votes each, and the accounting firm appointment garnering over 9.4 million votes in favor.
MIRA制药公司于2024年9月12日召开了2024年度股东大会,出席的股份占总股份的63.72%。股东选举了五位董事:Erez Aminov、Michael Jerman、Matthew Del Giudice万.D.、Denil Nanji Shekhat万.D.和Edward MacPherson,任期至下次年度会议。Cherry Bekaert LLP被任命为2024财年的独立注册公共会计师事务所,获得批准。股东还批准了对2022年全包激励计划的修订,以增加可用股份。提议在必要时休会的建议因其他提议获得通过而被撤回。投票结果显示所有提议得到了强烈的支持,董事提名人每人获得超过660万票,会计师事务所的任命获得超过940万票赞成。
MIRA制药公司于2024年9月12日召开了2024年度股东大会,出席的股份占总股份的63.72%。股东选举了五位董事:Erez Aminov、Michael Jerman、Matthew Del Giudice万.D.、Denil Nanji Shekhat万.D.和Edward MacPherson,任期至下次年度会议。Cherry Bekaert LLP被任命为2024财年的独立注册公共会计师事务所,获得批准。股东还批准了对2022年全包激励计划的修订,以增加可用股份。提议在必要时休会的建议因其他提议获得通过而被撤回。投票结果显示所有提议得到了强烈的支持,董事提名人每人获得超过660万票,会计师事务所的任命获得超过940万票赞成。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息